Martin Duvall appointed as chief executive officer of Tocagen
Mr. Duvall holds more than 30 years of experience in oncology drug development and commercialization at mid-stage and global pharmaceutical companies, including building numerous successful oncology teams.
Prior to joining Tocagen he served as executive vice president, chief commercial officer of ARIAD Pharmaceuticals, and helped lead the company’s transformation into a fully integrated, global biotechnology company.
Previous to Mr. Duvall’s role at ARIAD, he served as senior vice president and general manager, oncology, at Merck and & Co., Inc.
Prior to this role, Mr. Duvall was the senior vice president, global marketing and commercial operations at Abraxis Bioscience, Inc. (acquired by Celgene), where he guided global commercial strategy for Abraxane.
Prior to joining Abraxis, he was the senior vice president, commercial operations, for MGI Pharma, Inc. (acquired by Eisai Co., Ltd.), where he held a key role in the launch and commercialization of Aloxi.
Previous to MGI, Mr. Duvall held roles of increasing responsibility related to commercialization, marketing and sales of oncology drugs at Sanofi and its predecessor companies.
Mr. Duvall holds a master’s degree in chemistry from Johns Hopkins University, master’s degree in business from The University of Kansas and bachelor’s degree in chemistry from Muhlenberg College.
Harry Gruber, M.D., who previously served as Tocagen’s chief executive officer, has assumed the role of president, research and development, and will remain a member of Tocagen’s board of directors. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST